Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year

NCT03293524 is registered in ClinicalTrials.gov with GenSight Biologics as lead sponsor.

NCT NCT03293524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03293524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Lead sponsor
GenSight Biologics
Phase
Phase 3
Overall status
Completed
Start date
March 12, 2018
Completion date
July 23, 2024
Enrollment
98 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

leber hereditary optic neuropathy